Trial Profile

A randomized, double-blind, placebo-controlled, multicenter phase III clinical study on the efficacy and safety of tenapanor in the treatment of hyperphosphatemia in patients with end-stage renal disease-hemodialysis (ESRD-HD)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2025 According to a Fosun Pharma media release,the company announced that it has received approval from the National Medical Products Administration (NMPA) for the New Drug Application (NDA) for Tenapanor Hydrochloride Tablets.
29 Feb 2024 New trial record
12 Jul 2023 According to a Fosun Pharma USA media release, based on results form this study the company has submitted the New Drug Application (NDA) for Tenapanor Hydrochloride Tablets (the New Drug) for the control of hyperphosphatemia in adult patients with chronic kidney disease (CKD) on hemodialysis which was accepted for review by the National Medical Products Administration (NMPA).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com